Step 1: Apixaban belongs to the newer oral anticoagulants known as the direct oral anticoagulants (DOACs).
Step 2: It directly and reversibly inhibits activated factor X (factor Xa), the convergence point of the intrinsic and extrinsic coagulation pathways. Blocking factor Xa reduces thrombin generation and clot formation.
Step 3: It is used for treatment and prophylaxis of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, and for stroke prevention in atrial fibrillation. Hence the correct description is direct Xa inhibitor.
Step 4: Why the distractors are wrong: it does not act by inhibiting antithrombin (that pathway describes heparins, which enhance antithrombin); it is an anticoagulant, not a platelet activator; and it is not factor XII.